Related Experiment Video

Updated: Oct 2, 2025

Cardiac Response to β-Adrenergic Stimulation Determined by Pressure-Volume Loop Analysis
08:05

Cardiac Response to β-Adrenergic Stimulation Determined by Pressure-Volume Loop Analysis

Published on: May 19, 2021

3.8K

Nebivolol and incident cardiovascular events in hypertensive patients compared with nonvasodilatory beta blockers

Daniel M Huck1, Michael A Rosenberg1, Brian L Stauffer1,2

  • 1Division of Cardiology, Department of Medicine, University of Colorado, Aurora.

Journal of Hypertension
|February 24, 2022
PubMed

Insights

Nebivolol, a vasodilatory beta blocker, significantly reduced cardiovascular events in hypertensive patients compared to nonvasodilatory beta blockers like metoprolol. Further research is needed to confirm if this benefit is specific to nebivolol or a class effect.

Area of Science:

  • Cardiology
  • Pharmacology
  • Hypertension Management

Background:

  • Nonvasodilatory beta blockers show less cardiovascular event reduction than other antihypertensives.
  • Guidelines express uncertainty regarding the first-line use of beta blockers for hypertension.
  • Nebivolol, a third-generation vasodilatory beta blocker, possesses unique vascular benefits.

Purpose of the Study:

  • To compare cardiovascular outcomes in hypertensive patients treated with nebivolol versus nonvasodilatory beta blockers (metoprolol, atenolol).

Main Methods:

  • Retrospective cohort analysis of hypertensive adults within the University of Colorado health system.
  • Primary outcome: composite of heart failure, stroke, myocardial infarction, angina, or coronary revascularization.
  • Mahalanobis distance matching and Cox proportional hazards regression were employed for analysis.

Main Results:

  • Nebivolol use was associated with a 17% reduction in incident cardiovascular events compared to all nonvasodilatory beta blockers (HR 0.83, P=.004).
  • A 24% reduction in cardiovascular events was observed when comparing nebivolol to metoprolol (HR 0.76, P=.0001).
  • The matched cohort predominantly comprised women (54%) and non-Hispanic Caucasians (79%) with a median age of 58.

Conclusions:

  • The vasodilatory beta blocker nebivolol demonstrated reduced incident cardiovascular events compared to nonvasodilatory beta blockers.
  • Further investigation is required to ascertain if the observed benefits are a class effect of vasodilatory beta blockers or specific to nebivolol.

More Related Videos

Multiple Intravenous Bolus Dosing and Invasive Hemodynamic Assessment in a Hypoxia-Induced Mouse Pulmonary Artery Hypertension Model08:51

Multiple Intravenous Bolus Dosing and Invasive Hemodynamic Assessment in a Hypoxia-Induced Mouse Pulmonary Artery Hypertension Model

Published on: November 11, 2022

1.6K
Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker08:32

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

Published on: December 18, 2014

23.0K

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
459
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
765
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.1K
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
963
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
906
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
689